Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
Department
Adjust height of sidebar
KMap
Department
Senior VP Health Sciences
16 active people
104 grants
Recent Grants
Protocol Title: A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in Subjects with Acute Ischemic Stroke (AIS)
2024
·
$370.5K
stroke,
drug efficacy,
safety evaluation,
clinical trial,
ischemic stroke
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency?associated Liver Disease With Metavir
2023
·
$1.6M
clinical trial,
liver disease,
alpha-1 antitrypsin,
treatment,
safety
A First-in-human (FIH) Study of Inhibitory Interneurons (NRTX-1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)
2023
·
$749.8K
neuroscience,
epilepsy,
clinical trial,
drug resistance,
inhibitory interneurons
TRANSFORM: A 52-week, Randomized, Placebo-controlled, Double-blind, Adaptive Phase 2b/3 Trial of Setanaxib with a 52-week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elevate
2023
·
$641.6K
clinical trial,
drug therapy,
liver disease,
biomarker,
immunology
Phase 1/2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease
2023
·
$597.6K
parkinson's disease,
dose escalation,
clinical trial,
neurodegenerative diseases
Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)
2023
·
$568.2K
colorectal cancer,
treatment,
clinical trial,
dkn-01,
chemotherapy
A Phase 1b/2a Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy
2023
·
$543.6K
clinical trials,
pharmacology,
safety,
efficacy,
dose escalation
A Phase 4, Prospective, Multicenter, Single-Arm Study of a Mean Pulmonary Artery Pressure-Targeted Approach with Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Patient
2023
·
$509.1K
pulmonary hypertension,
right ventricular remodeling,
treprostinil therapy,
pulmonary artery pressure
A Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10mg as Adjunctive Therapy in Adult Participants with
2023
·
$502.5K
pharmacology,
mental health,
clinical trial,
pain management,
therapy
A Phase 4 Multicenter, Randomized, Double-Blind Study of Risankizumab for the Treatment of Adult Subjects with Moderate to Severe Genital Psoriasis or Moderate to Severe Scalp Psoriasis
2023
·
$457.5K
dermatology,
psoriasis,
clinical trial,
immunology,
skin diseases
A Phase 2b, Randomized, Double-Blind, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Treprostinil Palmitil Inhalation Powder (TPIP)
2023
·
$450K
pharmacokinetics,
drug safety,
clinical trial,
pulmonary hypertension,
drug efficacy
IMPAHCT-FUL: A Long-Term Extension, Multi-Center Safety Study of AV-101 in Subjects With Pulmonary Arterial Hypertension (PAH) Who Have Completed Study AV-101-002
2023
·
$436.7K
pulmonary arterial hypertension,
long-term safety,
av-101
A Multicenter, Randomized, Placebo Controlled, Double-blind, Parallel Group and Event Driven Phase 3 Study of the Oral Fxla Inhibitor Asundexian (Bay 2433334) for the Secondary Prevention of Ischemic
2023
·
$399.7K
clinical trials,
cardiovascular disease,
pharmacology,
ischemic events,
drug development
An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term use of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension
2023
·
$385.5K
pulmonary arterial hypertension,
treprostinil palmitil,
long-term safety,
tolerability,
effectiveness
Independent Hemocompatibility Assessment of ABIOMED Mechanical Circulatory Support Devices: Hemolysis and Platelet Activation Studies
2023
·
$350K
hemocompatibility,
mechanical circulatory support,
hemolysis,
platelet activation,
assessment
An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants with Major Depressive Disorder (MDD)
2023
·
$344.4K
mental health,
pharmacology,
clinical trials,
psychiatry,
geriatrics
A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor Xla Inhibitor, for Stroke Prevention After an Acute Is
2023
·
$341.3K
stroke prevention,
factor xa inhibitor,
efficacy and safety,
acute ischemic stroke
A Prospective, Multicenter, Single Blind, Randomized, Controlled Trial Evaluating the Safety and Effectiveness of the MOTIV Sirolimus-Eluting Bioresorbable Vascular Scaffold Compared with Plain Balloo
2023
·
$331.6K
clinical trial,
cardiology,
bioresorbable scaffold,
sirolimus-eluting,
vascular intervention
A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson?s Disease Patients With Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and i
2023
·
$308.7K
parkinson's disease,
dyskinesia,
efficacy,
safety/tolerability
A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn's Disease
2023
·
$306.6K
gastroenterology,
clinical trials,
therapeutics,
immunology
People
Alma Leon
Research Nurse III
Brent Gary
Clinical Research Coordinator II
Catherine Correia
Administrative Support Professional II
Daniel Duran
Clinical Research Coordinator I
David Elmer
Administrative Operations Manager V, Medicine
Austin Derma
Clinical Research Coordinator II
Gustavo Cornejo
Research Compliance Administrator II
Kirsten Anderson
Research Compliance Administrator IV
Kaitlyn Ammann
Researcher/Scientist III
Maria Ambrose
Research Specialist, Senior
Matthew Briggs
Assistant Professor of Practice
Maria Gordon
Clinical Research Manager II
Nirav Merchant
Research Program Administration Manager V
Pamela Ray
Financial Analysis Manager V
Angela Souza
Campus Planning Manager IV
Tanyha Zepeda
Database Administrator III
Research expenses history
Funding support
14 funding agencies since 2020